Premium
Characterization of Monocyte‐Derived Dendritic Cells from Immunosuppressed Renal Transplant Recipients with and without Squamous Cell Carcinomas
Author(s) -
Sandvik L. F.,
Volchenkov R.,
Jonsson R.,
Appel S.
Publication year - 2013
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12084
Subject(s) - peripheral blood mononuclear cell , medicine , chemokine , dendritic cell , monocyte , immunotherapy , immunology , cytokine , t cell , immune system , biology , in vitro , biochemistry
Renal transplant recipients ( RTR ) have a high risk of tumour development, especially cutaneous squamous cell carcinomas ( SCC ), due to long‐term immunosuppressive therapy. RTR may develop multiple lesions over short time periods, and these are often more aggressive with a higher risk of local recurrence and metastasis resulting in increased morbidity and mortality in these patients. Therefore, we took the first step towards evaluating the possibility of generating a therapeutic vaccine based on monocyte‐derived dendritic cells (mo DC ) for these patients. We analysed the phenotype and cytokine/chemokine profile of mo DC from long‐term immunosuppressed RTR with and without previous SCC . The number of peripheral blood mononuclear cells (PBMC) isolated per ml blood as well as the efficiency of generating mo DC from peripheral blood mononuclear cells ( PBMC ) was similar in patients and immunocompetent controls. Phenotype and cytokine/chemokine profile of the mo DC from immunosuppressed patients were similar to those from immunocompetent controls, making mo DC ‐based immunotherapy a potential future treatment option for RTR with multiple SCC .